Despite the high risk of nonadherence, patients with prediabetes and in GLP‐1 RA treatment were not associated with an increased risk of add‐on glucose‐lowering treatment, which could be indicative of an effective weight reduction and control of the HbA1c simply weight reduction, or adverse effects. The gene discussed is GLP1R; the disease is prediabetes syndrome.